pindolol has been researched along with Akinetic-Rigid Variant of Huntington Disease in 2 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waeber, C | 1 |
| Rigo, M | 1 |
| Chinaglia, G | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
| von Hafften, AH | 1 |
| Jensen, CF | 1 |
2 other studies available for pindolol and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
Topics: Aged; Aged, 80 and over; Autoradiography; Basal Ganglia; Binding Sites; Binding, Competitive; Female | 1991 |
Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease.
Topics: Aggression; Drug Therapy, Combination; Humans; Huntington Disease; Male; Middle Aged; Pindolol; Thio | 1989 |